Exagen Inc. (XGN)
XGN trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$8.48
+2.79% on the day
Market cap
$205.4M
Micro cap
Revenue · 2025
$66.6M
+19.7% on 2024
Net income · 2025
-$20.0M
-30.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | XGN on Nasdaq |
| Sector | Health Care |
| Industry | Medical Specialities |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001274737 |
| SEC industry code | Services-Medical Laboratories |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $66.6M |
| Net income | -$20.0M |
| Operating income | -$14.1M |
| Net margin | -30.0% |
| Operating margin | -21.1% |
| Revenue growth | +19.7% |
| Cash | $32.2M |
| Total assets | $58.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-06-20 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report 10-Q | 8-K | 2026-08-04 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 417 recent filings. All filings on EDGAR.
Peers in Medical Specialities
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TLSI | TriSalus Life Sciences Inc. | $4.00 | -3.38% | $246.3M |
| BDSX | Biodesix Inc. | $25.00 | -2.72% | $263.8M |
| BNR | Burning Rock Biotech Limited | $15.00 | 0.00% | $158.2M |
| YDES | YD Bio Limited | $6.10 | -3.63% | $432.1M |
| KEQU | Kewaunee Scientific Corporation | $32.20 | -0.62% | $93.2M |
| SERA | Sera Prognostics Inc. | $2.04 | -1.45% | $80.5M |
| FLGT | Fulgent Genetics Inc. | $21.06 | -1.91% | $579.5M |
| MDXH | MDxHealth SA | $0.6600 | +9.29% | $63.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier